Fujian Provincial Hospital
Welcome,         Profile    Billing    Logout  
 184 Trials 
387 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Hong
REPOSE-2, NCT05728775: REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry

Recruiting
4
7188
RoW
Remimazolam, Propofol
Nanfang Hospital of Southern Medical University
Anesthesia, Surgery-Complications
12/24
12/27
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
4
5000
RoW
Peginterferon Alfa-2B, Nucleoside Analogs
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
12/26
11/29
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting
2
280
RoW
Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Cancer
02/25
02/28
POEM, NCT04219033: Postoperative Cognitive Function and EEG

Recruiting
N/A
1250
RoW
EEG(Electroencephalogram) change
Air Force Military Medical University, China
Aging, Postoperative Cognitive Dysfunction, EEG With Periodic Abnormalities
03/23
04/23
NCT06308627: A One-year Trajectory of Depression Status Changes in Older Adults With MCI and SD: a Longitudinal Cohort Study

Completed
N/A
466
RoW
Fujian Medical University
Mild Cognitive Impairment, Subthreshold Depression, Older Adults
08/24
08/24
NCT05521295: Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome

Recruiting
N/A
3600
RoW
no intervention
Shengjing Hospital, Beijing Institutes of Life Science, Chinese Academy of Sciences
Infertility, Microbiome
09/23
09/24
REMAIN-2, NCT05962125: The Role of Periodic Alveolar Recruitment Maneuvers in Intraoperative Protective Ventilation

Completed
N/A
75
RoW
periodic alveolar recruitment maneuvers, positive end-expiratory pressure
Sixth Affiliated Hospital, Sun Yat-sen University
Mechanical Power, Alveolar Recruitment Maneuvers, Protective Ventilation, Postoperative Pulmonary Complications
11/23
12/23
NCT05442125: First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization

Recruiting
N/A
1146
RoW
Using DNA methylome to select embryos, Using morphologic score to select embryos
Shandong University, RenJi Hospital, Reproductive & Genetic Hospital of CITIC-Xiangya, Nanjing Maternity and Child Health Care Hospital, ShangHai Ji Ai Genetics & IVF Institute, Suzhou Municipal Hospital, The First Hospital of Jilin University, Sir Run Run Shaw Hospital, The Affiliated Hospital Of Guizhou Medical University, The Second Hospital of Hebei Medical University, Third Affiliated Hospital of Zhengzhou University, Ruijin Hospital, International Peace Maternity and Child Health Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Hainan Medical University, The First Affiliated Hospital of Anhui Medical University, Fujian Maternity and Child Health Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital with Nanjing Medical University, 900 th Hospital of Joint Logistics Support Force, Guangzhou Womenand Children's Medical Center, Changhai Hospital, Shenzhen Maternity & Child Healthcare Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Jining Medical University, Siriraj hospital, Mahidol university, Thailand
Reproductive Techniques, Assisted, DNA Methylation
06/24
05/25
NDURE2, NCT04030130: Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC

Completed
N/A
176
US
NDURE
Medical University of South Carolina, National Cancer Institute (NCI)
Squamous Cell Carcinoma of Head and Neck
12/23
01/24
NCT06706739: A Trial of Combined Subthreshold Depression in Older Adults With Mild Cognitive Impairment Participating in Art Games

Completed
N/A
87
RoW
Online art game intervention group
Fujian Medical University
Mild Cognitive Impairment, Subthreshold Depression
12/24
12/24
REMAIN-1, NCT05556174: Intraoperative Lung Protective Ventilation Needs Periodic Lung Recruitment Maneuvers

Completed
N/A
1060
RoW
periodic lung recruitment maneuvers
Sixth Affiliated Hospital, Sun Yat-sen University
Postoperative Complications, Abdominal Surgery, Intraoperative Mechanical Ventilation
09/24
11/24
NCT06926647: A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting
N/A
2000
RoW
Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα, comparative observation, drug withdrawal observation
Beijing 302 Hospital
HBV, Chronic Hepatitis b
12/28
12/28
NCT04989153: Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

Recruiting
N/A
5000
RoW
pepsinogen
Second Affiliated Hospital, School of Medicine, Zhejiang University, Jilin City People's Hospital, No. 924 Hospital of the People's Liberation Army of China, Kunshan Hospital of Traditional Chinese Medicine, Chinese PLA General Hospital, Sichuan Provincial People's Hospital, Affiliated Hospital of Southwest Medical University, Zhongshan Hospital Xiamen University, Jingzhou Hospital of Traditional Chinese Medicine, Changhai Hospital
Gastric Cancer, Precancerous Lesion, Helicobacter Pylori Infection
12/22
12/23
Zhang, Li
NCT05138705: Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

Completed
4
380
RoW
Quadrivalent Influenza Virus Split Vaccine
Shanghai Institute Of Biological Products
Influenza, Human
02/22
08/22
NCT03986528: Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting
4
334
RoW
Kanglaite Injection+Chemotherapy, Chemotherapy
Jie Li, Ministry of Science and Technology of the People´s Republic of China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
NSCLC
03/22
05/22
NCT05329038: Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

Active, not recruiting
4
180
RoW
Inactivated COVID-19 Vaccine, CoronaVac
Sinovac Life Sciences Co., Ltd.
COVID-19
06/22
02/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
4
5000
RoW
Peginterferon Alfa-2B, Nucleoside Analogs
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
12/26
11/29
FL-ALTER, NCT04028778: Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Recruiting
3
310
RoW
Gefitinib, Iressa, Anlotinib Hydrochloride, Placebo
Sun Yat-sen University
Lung Cancer, Nonsmall Cell
12/20
12/22
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

Not yet recruiting
3
352
RoW
olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen
Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
02/21
03/21
NCT04550949: To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Recruiting
3
700
RoW
QL1206, recombinant human anti-RANKL monoclonal antibody injection, Xgeva, Denosumab Injection
Qilu Pharmaceutical Co., Ltd.
Bone Metastases
03/21
06/22
RATIONALE 309, NCT03924986: Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

Checkmark Approved in China for 1L treatment of recurrent or metastatic nasopharyngeal cancer
Jun 2022 - Jun 2022: Approved in China for 1L treatment of recurrent or metastatic nasopharyngeal cancer
Checkmark Updated PFS and OS data from RATIONALE 309 study in 1L recurrent/metastatic nasopharyngeal cancer at ASCO 2022
Jun 2022 - Jun 2022: Updated PFS and OS data from RATIONALE 309 study in 1L recurrent/metastatic nasopharyngeal cancer at ASCO 2022
Checkmark Presentation of data from RATIONALE 309 trial for 1L recurrent or metastatic nasopharyngeal cancer at ASCO plenary series 2022
More
Completed
3
263
RoW
Tislelizumab, BGB-A317, Placebo, Gemcitabine, Cisplatin
BeiGene
Recurrent or Metastatic Nasopharyngeal Cancer
03/21
12/23
NCT03707509: Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
263
RoW
Camrelizumab, SHR-1210, Placebos, Placebo - Concentrate, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplantin Injection
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
08/21
12/22
TQB2450-III-05, NCT04325763: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
315
RoW
TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Stage III Non-small-cell Lung Cancer
12/22
03/25
ORIENT-11, NCT03607539: Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Checkmark FDA issued a complete response letter (CRL) for the BLA for Sintilimab injection in combination with pemetrexed.
Mar 2022 - Mar 2022: FDA issued a complete response letter (CRL) for the BLA for Sintilimab injection in combination with pemetrexed.
Hourglass Mar 2022 - Mar 2022 : PDUFA action date in US for the treatment of 1L NSCLC
Checkmark Accepted for review for the treatment of Nonsquamous NSCLC
May 2021 - May 2021: Accepted for review for the treatment of Nonsquamous NSCLC
More
Completed
3
397
RoW
Sintilimab, IBI308, Pemetrexed, Platinum, Placebos
Innovent Biologics (Suzhou) Co. Ltd.
Lung Neoplasms
02/23
02/23
PROFIT, NCT05509634: Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Completed
3
754
RoW
HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
Fujian Shengdi Pharmaceutical Co., Ltd.
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
06/23
08/23
NCT05683600: Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older

Terminated
3
3000
RoW
Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, Placebo
Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd.
COVID-19
07/23
07/23
NCT04951648: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Not yet recruiting
3
220
RoW
Almonertinib, HS-10296, chemotherapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
10/23
09/24
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

Recruiting
3
1041
RoW
YZJ-1139 20mg, YZJ-1139 40mg, Placebo
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Insomnia Disorder
12/24
12/24
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not yet recruiting
3
398
NA
JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection
Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC
03/27
03/28
BL-B01D1-301, NCT06382116: A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
3
428
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Pemetrexed+Cisplatin or Carboplatin
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/26
05/26
NCT06472908: Efficacy and Safety of Colchicine After PCI

Recruiting
3
8862
RoW
Colchicine 0.5 mg, no other name, Colchicine 0.375 mg, Placebo
Wuhan Union Hospital, China
Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
03/28
08/28
BL-B01D1-304, NCT06500026: A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer

Recruiting
3
714
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Topotecan
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
07/26
07/26
NCT06554184: HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Recruiting
3
700
RoW
HR20013 + dexamethasone + palonosetron placebo, Palonosetron + dexamethasone + HR20013 placebo
Fujian Shengdi Pharmaceutical Co., Ltd.
Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
09/25
09/25
NCT06735391: A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Recruiting
3
516
RoW
JMT101, Recombinant Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Injection, Osimertinib
Shanghai JMT-Bio Inc.
Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC
09/26
05/29
NCT06082635: TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting
3
297
RoW
TGRX-326, TGRX-326 QD (once a day), Crizotinib, Crizotinib 250 mg BID (twice a day)
Shenzhen TargetRx, Inc., Sun Yat-sen University
Non Small Cell Lung Cancer
12/24
11/28
HARMONi-A, NCT05184712: Phase 3 Clinical Study of AK112 for NSCLC Patients

Active, not recruiting
3
322
RoW
Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection
Akeso, Akeso
Non-Squamous Non-small Cell Lung Cancer
06/24
11/25
NCT06842199: Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting
3
360
RoW
ICP-488 Tablets, ICP-488 Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Plaque Psoriasis Patients
05/26
02/27
SKB264-Ⅲ-09, NCT05870319: A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Recruiting
3
356
RoW
SKB264, Pemetrexed, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/25
09/26
DUBHE-L-303, NCT05690945: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Recruiting
3
608
RoW
QL1706, PSB205, Tilesizumab, BGB-108
Qilu Pharmaceutical Co., Ltd.
Lung Cancer
06/29
12/29
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting
3
350
RoW
YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
Suzhou Puhe Pharmaceutical Technology Co., LTD
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
NCT06118333: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting
3
368
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, capecitabine, gemcitabine, docetaxel
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
12/25
12/25
NCT05943795: A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Recruiting
3
584
RoW
SI-B001, Docetaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung
07/26
07/26
NCT06319313: Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Not yet recruiting
2/3
534
NA
JMT101, docetaxel, HB1801
Shanghai JMT-Bio Inc.
Squamous Cell Non-small Cell Lung Cancer
07/26
12/27
NCT05020769: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Recruiting
2/3
14
RoW
SI-B001, Osimertinib
Sichuan Baili Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
06/25
06/25
DUBHE-N-302, NCT05576272: A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Active, not recruiting
2/3
460
RoW
QL1706, Carrelizumab, Gemcitabine, Cisplatin
Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
12/24
12/24
SURPASS, NCT05623267: Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Recruiting
2/3
346
RoW
Sugemalimab, Placebo
Sun Yat-sen University
Limited Stage Small Cell Lung Cancer
12/25
03/27
NCT03215693: X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Active, not recruiting
2
152
RoW
X-396 capsule, Ensartinib
Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
03/20
12/23
NCT04102982: Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

Recruiting
2
200
RoW
Camrelizumab, Camrelizumab plus microwave ablation, Camrelizumab plus MWA
Shandong Provincial Hospital
NSCLC Stage IV
10/21
02/22
NCT04164745: Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

Recruiting
2
49
RoW
Anlotinib, oral capsule, Pembrolizumab
Peking Union Medical College Hospital
NSCLC
11/21
11/22
JMT101-CSP-005, NCT06391944: JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Active, not recruiting
2
161
RoW
JMT101 Injection, Osimertinib tablet
Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation
05/23
11/26
KN046-209, NCT05420220: Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Recruiting
2
54
RoW
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Non-small Cell Lung Cancer
05/27
12/27
NCT04453930: A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Recruiting
2
60
RoW
Camrelizumab，an engineered anti-PD-1 antibody, SHR-1210, Platinum, Irinotecan, Apatinib
Peking Union Medical College Hospital
Small Cell Lung Carcinoma
06/23
06/23
NCT05162872: Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting
2
99
RoW
Niraparib，Sintilimab
Sun Yat-sen University
Nasopharyngeal Carcinoma
06/23
10/23
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Recruiting
2
75
RoW
ICP-332, ICP-332 Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Moderate to Severe Atopic Dermatitis
07/23
12/23
OptiTROP-Lung01, NCT05351788: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Recruiting
2
110
RoW
SKB264, KL-A167, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Non-small Cell Lung Cancer
08/24
04/26
NCT04459663: JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Not yet recruiting
2
50
RoW
Toripalimab injection combine with Axitinib
Li Zhang, MD
Non-small Cell Lung Cancer
09/23
12/23
BECOME, NCT05132777: Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Not yet recruiting
2
155
NA
JMT101, Osimertinib Mesylate Tablets
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
09/23
09/24
NCT06165380: Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
43
RoW
Cardenilimab Combined With Chemotherapy
Li Zhang
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
12/24
12/25
EAGLE, NCT05491811: Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Active, not recruiting
2
49
RoW
Ensartinib, Bevacizumab, MIL60
Sun Yat-sen University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shenyang Chest Hospital, Hebei Medical University Fourth Hospital, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Guangzhou Institute of Respiratory Disease, Central People's Hospital of Zhanjiang, Guangdong Provincial Agricultural Reclamation Central Hospital, Wuhan Union Hospital, China, West China Hospital, The First Affiliated Hospital with Nanjing Medical University, Yuebei People's Hospital, Yunnan Cancer Hospital
Non-Small Cell Lung Cancer
08/24
12/26
GASTO-1091, NCT04085250: Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Active, not recruiting
2
264
RoW
Neoadjuvant therapy, Chemotherapy concurrent with radiotherapy, Radiotherapy, Nivolumab, Observation
Sun Yat-sen University
Stage III Non-small-cell Lung Cancer
01/25
01/25
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Completed
2
34
RoW
Chidamide, CS055, Envafolimab, KN035
Chipscreen Biosciences, Ltd.
Non Small Cell Lung Cancer
02/23
05/24
NCT05020457: SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Recruiting
2
60
RoW
SI-B001, AP or TP, AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin., Docetaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
06/25
06/25
NCT04844970: Anamorelin Study for Advanced Pancreatic Cancer

Recruiting
2
100
US
Anamorelin Hydrochloride, Placebo
Lahey Clinic, Helsinn Healthcare SA, Quartesian LLC
Metastatic Pancreatic Cancer
12/24
12/24
NCT05955391: TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
157
RoW
TGRX-326
Shenzhen TargetRx, Inc., Sun Yat-sen University, Tongji Hospital, Sichuan Cancer Hospital and Research Institute, The First Affiliated Hospital of Zhengzhou University, West China Hospital, Zhejiang University, Jilin Provincial Tumor Hospital, Hunan Cancer Hospital, Shandong Cancer Hospital and Institute, Jiangxi Provincial Cancer Hospital, First Hospital of China Medical University, The Affiliated Hospital of Qingdao University, Liaoning Tumor Hospital & Institute, Haerbin Medical University Cancer Hospital, Xinxiang Central Hospital, Xiangyang Central Hospital, Mianyang Central Hospital, Zhejiang Cancer Hospital, Henan Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Bengbu Medical College, Chinese Academy of Medical Science Cancer Hospital, Shenzhen Center, Bingzhou Medical University Affiliated Hospital, Fujian Cancer Hospital, Ningbo No. 1 Hospital, First Affiliated Hospital Xi'an Jiaotong University, The Second Affiliated Hospital of AFMU, Yunnan Cancer Hospital, Capital Medical School Beijing Chest Hospital, Shijiazhuang People's Hospital, Tianjin Cancer Hospital, Affiliated Cancer Hospital of Guizhou Medical University, Nanchang University First Affiliated Hospital, Jingzhou First People's Hospital, Shanghai Chest Hospital
Non-small Cell Lung Cancer
02/24
08/24
AK112-201, NCT04736823: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

Recruiting
2
296
RoW
AK112, Pemetrexed, Paclitaxel, Carboplatin, Docetaxel
Akeso
NSCLC
07/25
12/26
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Recruiting
2
160
RoW
TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Atopic Dermatitis
03/24
03/24
BL-B01D1-204-05, NCT06475300: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting
2
332
RoW
BL-B01D1, PD-1 Monoclonal Antibody
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
07/26
07/26
NCT05513573: Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

Active, not recruiting
2
75
RoW
HLX07, HLX10, placebo, chemotherapy
Shanghai Henlius Biotech
Nasopharyngeal Carcinoma by AJCC V8 Stage
09/24
09/26
NCT06514027: Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Not yet recruiting
2
30
RoW
BEBT-109 Capsules, KCBT-1083, Pemetrexed Disodium for Injection, Carboplatin Injection, Cisplatin Injection
BeBetter Med Inc
Non Small Cell Lung Cancer
06/27
11/27
TQB2102-II-03, NCT06496490: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Recruiting
2
270
RoW
TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
10/25
02/26
NCT04992858: Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Not yet recruiting
2
80
NA
CT053PTSA, Ningetinib
Sunshine Lake Pharma Co., Ltd.
Advanced NSCLC
09/24
12/24
NCT05847764: Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruiting
2
95
RoW
RC48+Tislelizumab+carboplatin, RC48+Furmonertinib, 1L, RC48+Furmonertinib, 2L+
Sun Yat-sen University
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin
10/24
05/25
OptiTROP-Lung03, NCT05631262: SKB264 Monotherapy in Selected Subjects with Advanced Solid Tumors

Active, not recruiting
2
321
RoW
SKB264, Docetaxel
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Selected Subjects with Advanced Solid Tumors
12/25
12/25
JSKN016-201, NCT06775483: Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

Not yet recruiting
2
220
NA
JSKN016, Docetaxel
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Non-small Cell Lung Cancer
06/27
11/27
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting
2
280
RoW
Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Cancer
02/25
02/28
OCEANII, NCT05195632: Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer

Active, not recruiting
2
63
RoW
Encorafenib, PF-07263896 or W0090 (in Europe), LGX818 (in US), ONO-7702 (in Japan), Binimetinib, W0074 (in Europe), MEK162 (in US), ARRY-438162 (in US), ONO-7703 (in Japan)
Pierre Fabre Medicament
Non-Small Cell Lung Cancer
05/25
05/25
NCT06927687: Study of ZG005 in Patients With Advanced Solid Tumors

Not yet recruiting
2
100
RoW
ZG005 for Injection, ZG005
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Advanced Solid Tumor
05/27
06/27
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting
2
121
RoW
BL-B01D1, SI-B003
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
11/25
11/25
NCT05588609: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Active, not recruiting
2
90
US
Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab
Merus N.V.
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
10/25
03/26
SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
SHR-1701-II-203-NPC, NCT05020925: SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting
1/2
30
RoW
SHR-1701, SHR-1701 Injection, Famitinib, SHR-1020
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
05/22
02/24
TQB2858-Ib-01, NCT05198531: To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Recruiting
1/2
90
RoW
TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection, Cisplatin Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recurrent / Metastatic Nasopharyngeal Cancer
10/22
08/23
NCT04237805 / 2013-001045-14: A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
280
RoW
SAF-189s, foritinib succinate
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell
12/22
03/26
AK104-207, NCT04647344: A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Completed
1/2
46
RoW
AK104 plus Carboplatin and Pemetrexed, AK104 plus Carboplatin and paclitaxel
Akeso
Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
12/23
12/23
NCT04775680: Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Terminated
1/2
25
RoW
ADG106 injection, PD-1 antibody injection
Adagene (Suzhou) Limited
Solid Tumor, Non Hodgkin Lymphoma
02/23
02/23
NCT03758287: Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Active, not recruiting
1/2
158
RoW
CT053PTSA, Ningetinib, Gefitinib, Iressa
Sunshine Lake Pharma Co., Ltd.
Non-small Cell Lung Cancer
07/23
07/23
NCT05016544: Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Recruiting
1/2
48
RoW
inetetamab, Pytotinib
Sun Yat-sen University
Non-small Cell Lung Cancer
08/23
02/25
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting
1/2
183
Japan, US, RoW
Glumetinib, SCC244
Haihe Biopharma Co., Ltd.
C-Met Exon 14 Mutation
10/23
12/23
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors

Recruiting
1/2
200
RoW
LBL-007 Injection, LBL-007, Toripalimab Injection
Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumor
06/25
08/25
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Recruiting
1/2
160
RoW
YK-029A
Suzhou Puhe Pharmaceutical Technology Co., LTD
Treatment, Treatment Side Effects
12/23
05/24
NCT05284994: TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Recruiting
1/2
160
RoW
TQ-B3525 Tablets, Osimertinib Mesylate Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nonsmall-cell Lung Cancer
04/24
06/24
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting
1/2
133
RoW
KC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Digestive System Tumors
10/25
12/25
NCT05173805: Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation

Enrolling by invitation
1/2
150
RoW
YL-15293
Shanghai YingLi Pharmaceutical Co. Ltd.
Advanced Solid Tumor
04/24
12/24
PRO1160-001, NCT05721222: PRO1160 for Advanced Solid and Liquid Tumors

Recruiting
1/2
134
US, RoW
PRO1160
ProfoundBio US Co.
Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
11/26
03/27
NCT05824455: A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors

Terminated
1/2
4
RoW
JS109 combine with irinotecan
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd., Sponsor GmbH
Advanced Solid Tumors
09/23
09/23
LBL-007-CN-004, NCT05516914: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Recruiting
1/2
490
RoW
LBL-007 Injection, LBL-007, Tislelizumab Injection, Tislelizumab, Cisplatin Injection, Cisplatin, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride, Docetaxel injection, Docetaxel
Nanjing Leads Biolabs Co.,Ltd
Malignant Tumors
10/25
12/25
NCT05505877: Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

Recruiting
1/2
160
RoW
BR790+Tislelizumab
Shanghai Gopherwood Biotech Co., Ltd.
Advanced Solid Tumor
10/24
12/24
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Li, Hong
REPOSE-2, NCT05728775: REmimazolam vs Propofol Total Intravenous Anesthesia on Outcomes After Major Noncardiac SurgEry

Recruiting
4
7188
RoW
Remimazolam, Propofol
Nanfang Hospital of Southern Medical University
Anesthesia, Surgery-Complications
12/24
12/27
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
4
5000
RoW
Peginterferon Alfa-2B, Nucleoside Analogs
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
12/26
11/29
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting
2
280
RoW
Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Cancer
02/25
02/28
POEM, NCT04219033: Postoperative Cognitive Function and EEG

Recruiting
N/A
1250
RoW
EEG(Electroencephalogram) change
Air Force Military Medical University, China
Aging, Postoperative Cognitive Dysfunction, EEG With Periodic Abnormalities
03/23
04/23
NCT06308627: A One-year Trajectory of Depression Status Changes in Older Adults With MCI and SD: a Longitudinal Cohort Study

Completed
N/A
466
RoW
Fujian Medical University
Mild Cognitive Impairment, Subthreshold Depression, Older Adults
08/24
08/24
NCT05521295: Frozen Embryo Transfer Pregnancy Outcomes Prediction by Microbiome

Recruiting
N/A
3600
RoW
no intervention
Shengjing Hospital, Beijing Institutes of Life Science, Chinese Academy of Sciences
Infertility, Microbiome
09/23
09/24
REMAIN-2, NCT05962125: The Role of Periodic Alveolar Recruitment Maneuvers in Intraoperative Protective Ventilation

Completed
N/A
75
RoW
periodic alveolar recruitment maneuvers, positive end-expiratory pressure
Sixth Affiliated Hospital, Sun Yat-sen University
Mechanical Power, Alveolar Recruitment Maneuvers, Protective Ventilation, Postoperative Pulmonary Complications
11/23
12/23
NCT05442125: First Live Birth Rate With eSET After Preimplantation Methylome Screening (PIMS) Versus Conventional In-vitro Fertilization

Recruiting
N/A
1146
RoW
Using DNA methylome to select embryos, Using morphologic score to select embryos
Shandong University, RenJi Hospital, Reproductive & Genetic Hospital of CITIC-Xiangya, Nanjing Maternity and Child Health Care Hospital, ShangHai Ji Ai Genetics & IVF Institute, Suzhou Municipal Hospital, The First Hospital of Jilin University, Sir Run Run Shaw Hospital, The Affiliated Hospital Of Guizhou Medical University, The Second Hospital of Hebei Medical University, Third Affiliated Hospital of Zhengzhou University, Ruijin Hospital, International Peace Maternity and Child Health Hospital, Henan Provincial People's Hospital, The First Affiliated Hospital of Hainan Medical University, The First Affiliated Hospital of Anhui Medical University, Fujian Maternity and Child Health Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital with Nanjing Medical University, 900 th Hospital of Joint Logistics Support Force, Guangzhou Womenand Children's Medical Center, Changhai Hospital, Shenzhen Maternity & Child Healthcare Hospital, Sixth Affiliated Hospital, Sun Yat-sen University, Liuzhou Hospital of Guangzhou Women and Children's Medical Center, Jining Medical University, Siriraj hospital, Mahidol university, Thailand
Reproductive Techniques, Assisted, DNA Methylation
06/24
05/25
NDURE2, NCT04030130: Navigation vs Usual Care for Timely Adjuvant Therapy for Patients With Locally Advanced HNSCC

Completed
N/A
176
US
NDURE
Medical University of South Carolina, National Cancer Institute (NCI)
Squamous Cell Carcinoma of Head and Neck
12/23
01/24
NCT06706739: A Trial of Combined Subthreshold Depression in Older Adults With Mild Cognitive Impairment Participating in Art Games

Completed
N/A
87
RoW
Online art game intervention group
Fujian Medical University
Mild Cognitive Impairment, Subthreshold Depression
12/24
12/24
REMAIN-1, NCT05556174: Intraoperative Lung Protective Ventilation Needs Periodic Lung Recruitment Maneuvers

Completed
N/A
1060
RoW
periodic lung recruitment maneuvers
Sixth Affiliated Hospital, Sun Yat-sen University
Postoperative Complications, Abdominal Surgery, Intraoperative Mechanical Ventilation
09/24
11/24
NCT06926647: A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B

Not yet recruiting
N/A
2000
RoW
Nucleos(t)ide Analogues, Interferon alfa, NAs combined with IFNα, comparative observation, drug withdrawal observation
Beijing 302 Hospital
HBV, Chronic Hepatitis b
12/28
12/28
NCT04989153: Nasal Endoscopic Screening and Risk Assessment for Early Gastric Cancer

Recruiting
N/A
5000
RoW
pepsinogen
Second Affiliated Hospital, School of Medicine, Zhejiang University, Jilin City People's Hospital, No. 924 Hospital of the People's Liberation Army of China, Kunshan Hospital of Traditional Chinese Medicine, Chinese PLA General Hospital, Sichuan Provincial People's Hospital, Affiliated Hospital of Southwest Medical University, Zhongshan Hospital Xiamen University, Jingzhou Hospital of Traditional Chinese Medicine, Changhai Hospital
Gastric Cancer, Precancerous Lesion, Helicobacter Pylori Infection
12/22
12/23
Zhang, Li
NCT05138705: Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years

Completed
4
380
RoW
Quadrivalent Influenza Virus Split Vaccine
Shanghai Institute Of Biological Products
Influenza, Human
02/22
08/22
NCT03986528: Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)

Recruiting
4
334
RoW
Kanglaite Injection+Chemotherapy, Chemotherapy
Jie Li, Ministry of Science and Technology of the People´s Republic of China, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
NSCLC
03/22
05/22
NCT05329038: Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

Active, not recruiting
4
180
RoW
Inactivated COVID-19 Vaccine, CoronaVac
Sinovac Life Sciences Co., Ltd.
COVID-19
06/22
02/24
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)

Active, not recruiting
4
8250
RoW
Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy
Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases
04/25
04/25
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients

Recruiting
4
5000
RoW
Peginterferon Alfa-2B, Nucleoside Analogs
Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B, Chronic
12/26
11/29
FL-ALTER, NCT04028778: Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC

Recruiting
3
310
RoW
Gefitinib, Iressa, Anlotinib Hydrochloride, Placebo
Sun Yat-sen University
Lung Cancer, Nonsmall Cell
12/20
12/22
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

Not yet recruiting
3
352
RoW
olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen
Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
02/21
03/21
NCT04550949: To Evaluate the Efficacy and Safety of QL1206 and Xgeva in Patients With Bone Metastases From Solid Tumors

Recruiting
3
700
RoW
QL1206, recombinant human anti-RANKL monoclonal antibody injection, Xgeva, Denosumab Injection
Qilu Pharmaceutical Co., Ltd.
Bone Metastases
03/21
06/22
RATIONALE 309, NCT03924986: Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)

Checkmark Approved in China for 1L treatment of recurrent or metastatic nasopharyngeal cancer
Jun 2022 - Jun 2022: Approved in China for 1L treatment of recurrent or metastatic nasopharyngeal cancer
Checkmark Updated PFS and OS data from RATIONALE 309 study in 1L recurrent/metastatic nasopharyngeal cancer at ASCO 2022
Jun 2022 - Jun 2022: Updated PFS and OS data from RATIONALE 309 study in 1L recurrent/metastatic nasopharyngeal cancer at ASCO 2022
Checkmark Presentation of data from RATIONALE 309 trial for 1L recurrent or metastatic nasopharyngeal cancer at ASCO plenary series 2022
More
Completed
3
263
RoW
Tislelizumab, BGB-A317, Placebo, Gemcitabine, Cisplatin
BeiGene
Recurrent or Metastatic Nasopharyngeal Cancer
03/21
12/23
NCT03707509: Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
3
263
RoW
Camrelizumab, SHR-1210, Placebos, Placebo - Concentrate, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplantin Injection
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
08/21
12/22
TQB2450-III-05, NCT04325763: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
315
RoW
TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Stage III Non-small-cell Lung Cancer
12/22
03/25
ORIENT-11, NCT03607539: Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC

Checkmark FDA issued a complete response letter (CRL) for the BLA for Sintilimab injection in combination with pemetrexed.
Mar 2022 - Mar 2022: FDA issued a complete response letter (CRL) for the BLA for Sintilimab injection in combination with pemetrexed.
Hourglass Mar 2022 - Mar 2022 : PDUFA action date in US for the treatment of 1L NSCLC
Checkmark Accepted for review for the treatment of Nonsquamous NSCLC
May 2021 - May 2021: Accepted for review for the treatment of Nonsquamous NSCLC
More
Completed
3
397
RoW
Sintilimab, IBI308, Pemetrexed, Platinum, Placebos
Innovent Biologics (Suzhou) Co. Ltd.
Lung Neoplasms
02/23
02/23
PROFIT, NCT05509634: Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors

Completed
3
754
RoW
HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
Fujian Shengdi Pharmaceutical Co., Ltd.
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
06/23
08/23
NCT05683600: Efficacy and Safety of COVID-19 Vaccine as Booster Vaccination in Adults 18 Years of Age or Older

Terminated
3
3000
RoW
Recombinant SARS-CoV-2 Vaccine (CHO Cell) LYB001, Placebo
Guangzhou Patronus Biotech Co., Ltd., Yantai Patronus Biotech Co., Ltd.
COVID-19
07/23
07/23
NCT04951648: A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation

Not yet recruiting
3
220
RoW
Almonertinib, HS-10296, chemotherapy
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
10/23
09/24
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

Recruiting
3
1041
RoW
YZJ-1139 20mg, YZJ-1139 40mg, Placebo
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Insomnia Disorder
12/24
12/24
NCT06380348: JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Not yet recruiting
3
398
NA
JMT101 Injection, Osimertinib tablet, Cisplatin injection, Pemetrexed injection
Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC
03/27
03/28
BL-B01D1-301, NCT06382116: A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
3
428
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Pemetrexed+Cisplatin or Carboplatin
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/26
05/26
NCT06472908: Efficacy and Safety of Colchicine After PCI

Recruiting
3
8862
RoW
Colchicine 0.5 mg, no other name, Colchicine 0.375 mg, Placebo
Wuhan Union Hospital, China
Coronary Heart Disease, Percutaneous Coronary Intervention, Colchicine
03/28
08/28
BL-B01D1-304, NCT06500026: A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer

Recruiting
3
714
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, Topotecan
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Small Cell Lung Cancer
07/26
07/26
NCT06554184: HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents

Recruiting
3
700
RoW
HR20013 + dexamethasone + palonosetron placebo, Palonosetron + dexamethasone + HR20013 placebo
Fujian Shengdi Pharmaceutical Co., Ltd.
Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents
09/25
09/25
NCT06735391: A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Recruiting
3
516
RoW
JMT101, Recombinant Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Injection, Osimertinib
Shanghai JMT-Bio Inc.
Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC
09/26
05/29
NCT06082635: TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting
3
297
RoW
TGRX-326, TGRX-326 QD (once a day), Crizotinib, Crizotinib 250 mg BID (twice a day)
Shenzhen TargetRx, Inc., Sun Yat-sen University
Non Small Cell Lung Cancer
12/24
11/28
HARMONi-A, NCT05184712: Phase 3 Clinical Study of AK112 for NSCLC Patients

Active, not recruiting
3
322
RoW
Ivonescimab (SMT112 or AK112) Injection, Pemetrexed, Carboplatin, Placebo Injection
Akeso, Akeso
Non-Squamous Non-small Cell Lung Cancer
06/24
11/25
NCT06842199: Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

Recruiting
3
360
RoW
ICP-488 Tablets, ICP-488 Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Plaque Psoriasis Patients
05/26
02/27
SKB264-Ⅲ-09, NCT05870319: A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Recruiting
3
356
RoW
SKB264, Pemetrexed, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
05/25
09/26
DUBHE-L-303, NCT05690945: A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

Recruiting
3
608
RoW
QL1706, PSB205, Tilesizumab, BGB-108
Qilu Pharmaceutical Co., Ltd.
Lung Cancer
06/29
12/29
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting
3
350
RoW
YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
Suzhou Puhe Pharmaceutical Technology Co., LTD
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
NCT06118333: A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting
3
368
RoW
BL-B01D1, iza-bren, izalontamab brengitecan, BMS-986507, capecitabine, gemcitabine, docetaxel
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
12/25
12/25
NCT05943795: A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Recruiting
3
584
RoW
SI-B001, Docetaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Non-small Cell Lung Adenocarcinoma, Squamous Cell Carcinoma of Lung
07/26
07/26
NCT06319313: Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Not yet recruiting
2/3
534
NA
JMT101, docetaxel, HB1801
Shanghai JMT-Bio Inc.
Squamous Cell Non-small Cell Lung Cancer
07/26
12/27
NCT05020769: SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Recruiting
2/3
14
RoW
SI-B001, Osimertinib
Sichuan Baili Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
06/25
06/25
DUBHE-N-302, NCT05576272: A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Active, not recruiting
2/3
460
RoW
QL1706, Carrelizumab, Gemcitabine, Cisplatin
Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
12/24
12/24
SURPASS, NCT05623267: Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

Recruiting
2/3
346
RoW
Sugemalimab, Placebo
Sun Yat-sen University
Limited Stage Small Cell Lung Cancer
12/25
03/27
NCT03215693: X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Active, not recruiting
2
152
RoW
X-396 capsule, Ensartinib
Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer
03/20
12/23
NCT04102982: Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

Recruiting
2
200
RoW
Camrelizumab, Camrelizumab plus microwave ablation, Camrelizumab plus MWA
Shandong Provincial Hospital
NSCLC Stage IV
10/21
02/22
NCT04164745: Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

Recruiting
2
49
RoW
Anlotinib, oral capsule, Pembrolizumab
Peking Union Medical College Hospital
NSCLC
11/21
11/22
JMT101-CSP-005, NCT06391944: JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

Active, not recruiting
2
161
RoW
JMT101 Injection, Osimertinib tablet
Shanghai JMT-Bio Inc.
Local Advanced or Metastatic NSCLC, Harboring EGFR Common Mutation
05/23
11/26
KN046-209, NCT05420220: Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

Recruiting
2
54
RoW
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection), Axitinib
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Non-small Cell Lung Cancer
05/27
12/27
NCT04453930: A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Recruiting
2
60
RoW
Camrelizumab，an engineered anti-PD-1 antibody, SHR-1210, Platinum, Irinotecan, Apatinib
Peking Union Medical College Hospital
Small Cell Lung Carcinoma
06/23
06/23
NCT05162872: Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma

Recruiting
2
99
RoW
Niraparib，Sintilimab
Sun Yat-sen University
Nasopharyngeal Carcinoma
06/23
10/23
NCT05702268: Pharmacodynamic Blood Characteristics of ICP-332 in Patients With Moderate to Severe Atopic Dermatitis

Recruiting
2
75
RoW
ICP-332, ICP-332 Placebo
Beijing InnoCare Pharma Tech Co., Ltd.
Moderate to Severe Atopic Dermatitis
07/23
12/23
OptiTROP-Lung01, NCT05351788: SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Recruiting
2
110
RoW
SKB264, KL-A167, Carboplatin, Cisplatin
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Non-small Cell Lung Cancer
08/24
04/26
NCT04459663: JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.

Not yet recruiting
2
50
RoW
Toripalimab injection combine with Axitinib
Li Zhang, MD
Non-small Cell Lung Cancer
09/23
12/23
BECOME, NCT05132777: Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Not yet recruiting
2
155
NA
JMT101, Osimertinib Mesylate Tablets
Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations
09/23
09/24
NCT06165380: Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting
2
43
RoW
Cardenilimab Combined With Chemotherapy
Li Zhang
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapies
12/24
12/25
EAGLE, NCT05491811: Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Active, not recruiting
2
49
RoW
Ensartinib, Bevacizumab, MIL60
Sun Yat-sen University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shenyang Chest Hospital, Hebei Medical University Fourth Hospital, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Guangzhou Institute of Respiratory Disease, Central People's Hospital of Zhanjiang, Guangdong Provincial Agricultural Reclamation Central Hospital, Wuhan Union Hospital, China, West China Hospital, The First Affiliated Hospital with Nanjing Medical University, Yuebei People's Hospital, Yunnan Cancer Hospital
Non-Small Cell Lung Cancer
08/24
12/26
GASTO-1091, NCT04085250: Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy

Active, not recruiting
2
264
RoW
Neoadjuvant therapy, Chemotherapy concurrent with radiotherapy, Radiotherapy, Nivolumab, Observation
Sun Yat-sen University
Stage III Non-small-cell Lung Cancer
01/25
01/25
NCT05068427: Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

Completed
2
34
RoW
Chidamide, CS055, Envafolimab, KN035
Chipscreen Biosciences, Ltd.
Non Small Cell Lung Cancer
02/23
05/24
NCT05020457: SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Recruiting
2
60
RoW
SI-B001, AP or TP, AP chemotherapy regimen was pemetrexed combined with cisplatin, and TP chemotherapy regimen was paclitaxel combined with cisplatin., Docetaxel
Sichuan Baili Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
06/25
06/25
NCT04844970: Anamorelin Study for Advanced Pancreatic Cancer

Recruiting
2
100
US
Anamorelin Hydrochloride, Placebo
Lahey Clinic, Helsinn Healthcare SA, Quartesian LLC
Metastatic Pancreatic Cancer
12/24
12/24
NCT05955391: TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
157
RoW
TGRX-326
Shenzhen TargetRx, Inc., Sun Yat-sen University, Tongji Hospital, Sichuan Cancer Hospital and Research Institute, The First Affiliated Hospital of Zhengzhou University, West China Hospital, Zhejiang University, Jilin Provincial Tumor Hospital, Hunan Cancer Hospital, Shandong Cancer Hospital and Institute, Jiangxi Provincial Cancer Hospital, First Hospital of China Medical University, The Affiliated Hospital of Qingdao University, Liaoning Tumor Hospital & Institute, Haerbin Medical University Cancer Hospital, Xinxiang Central Hospital, Xiangyang Central Hospital, Mianyang Central Hospital, Zhejiang Cancer Hospital, Henan Cancer Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Bengbu Medical College, Chinese Academy of Medical Science Cancer Hospital, Shenzhen Center, Bingzhou Medical University Affiliated Hospital, Fujian Cancer Hospital, Ningbo No. 1 Hospital, First Affiliated Hospital Xi'an Jiaotong University, The Second Affiliated Hospital of AFMU, Yunnan Cancer Hospital, Capital Medical School Beijing Chest Hospital, Shijiazhuang People's Hospital, Tianjin Cancer Hospital, Affiliated Cancer Hospital of Guizhou Medical University, Nanchang University First Affiliated Hospital, Jingzhou First People's Hospital, Shanghai Chest Hospital
Non-small Cell Lung Cancer
02/24
08/24
AK112-201, NCT04736823: A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC

Recruiting
2
296
RoW
AK112, Pemetrexed, Paclitaxel, Carboplatin, Docetaxel
Akeso
NSCLC
07/25
12/26
NCT05970432: A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Recruiting
2
160
RoW
TQH2722 injection 300mg-150mg, TQH2722 injection 600mg-300mg, TQH2722 injection 900mg-450mg, TQH2722 injection matching Placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Atopic Dermatitis
03/24
03/24
BL-B01D1-204-05, NCT06475300: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting
2
332
RoW
BL-B01D1, PD-1 Monoclonal Antibody
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, Solid Tumor
07/26
07/26
NCT05513573: Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

Active, not recruiting
2
75
RoW
HLX07, HLX10, placebo, chemotherapy
Shanghai Henlius Biotech
Nasopharyngeal Carcinoma by AJCC V8 Stage
09/24
09/26
NCT06514027: Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Not yet recruiting
2
30
RoW
BEBT-109 Capsules, KCBT-1083, Pemetrexed Disodium for Injection, Carboplatin Injection, Cisplatin Injection
BeBetter Med Inc
Non Small Cell Lung Cancer
06/27
11/27
TQB2102-II-03, NCT06496490: A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality

Recruiting
2
270
RoW
TQB2102 for injection, TQB2102 for injection combined with Benmelstobart injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
10/25
02/26
NCT04992858: Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Not yet recruiting
2
80
NA
CT053PTSA, Ningetinib
Sunshine Lake Pharma Co., Ltd.
Advanced NSCLC
09/24
12/24
NCT05847764: Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Not yet recruiting
2
95
RoW
RC48+Tislelizumab+carboplatin, RC48+Furmonertinib, 1L, RC48+Furmonertinib, 2L+
Sun Yat-sen University
Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, RC48, Disitamab Vedotin
10/24
05/25
OptiTROP-Lung03, NCT05631262: SKB264 Monotherapy in Selected Subjects with Advanced Solid Tumors

Active, not recruiting
2
321
RoW
SKB264, Docetaxel
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Selected Subjects with Advanced Solid Tumors
12/25
12/25
JSKN016-201, NCT06775483: Evaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical Study

Not yet recruiting
2
220
NA
JSKN016, Docetaxel
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Non-small Cell Lung Cancer
06/27
11/27
FOCUS-C, NCT05334277: Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA

Recruiting
2
280
RoW
Furmonertinib, AST2818, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
Sun Yat-sen University, Allist Pharmaceuticals, Inc., GeneCast Biotechnology Co., Ltd.
Non-small Cell Lung Cancer
02/25
02/28
OCEANII, NCT05195632: Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer

Active, not recruiting
2
63
RoW
Encorafenib, PF-07263896 or W0090 (in Europe), LGX818 (in US), ONO-7702 (in Japan), Binimetinib, W0074 (in Europe), MEK162 (in US), ARRY-438162 (in US), ONO-7703 (in Japan)
Pierre Fabre Medicament
Non-Small Cell Lung Cancer
05/25
05/25
NCT06927687: Study of ZG005 in Patients With Advanced Solid Tumors

Not yet recruiting
2
100
RoW
ZG005 for Injection, ZG005
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Advanced Solid Tumor
05/27
06/27
NCT05956587: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Recruiting
2
121
RoW
BL-B01D1, SI-B003
Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
11/25
11/25
NCT05588609: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Active, not recruiting
2
90
US
Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab
Merus N.V.
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
10/25
03/26
SKB264-II-04, NCT05816252: A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer () (MK-2870-003)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Sacituzumab Tirumotecan (Sac-TMT), Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
SHR-1701-II-203-NPC, NCT05020925: SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting
1/2
30
RoW
SHR-1701, SHR-1701 Injection, Famitinib, SHR-1020
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
05/22
02/24
TQB2858-Ib-01, NCT05198531: To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Recruiting
1/2
90
RoW
TQB2858 Injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride injection, Cisplatin Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Recurrent / Metastatic Nasopharyngeal Cancer
10/22
08/23
NCT04237805 / 2013-001045-14: A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
280
RoW
SAF-189s, foritinib succinate
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell
12/22
03/26
AK104-207, NCT04647344: A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Completed
1/2
46
RoW
AK104 plus Carboplatin and Pemetrexed, AK104 plus Carboplatin and paclitaxel
Akeso
Lung Cancer Non-Small Cell Stage IIIB/IIIC/IV
12/23
12/23
NCT04775680: Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma

Terminated
1/2
25
RoW
ADG106 injection, PD-1 antibody injection
Adagene (Suzhou) Limited
Solid Tumor, Non Hodgkin Lymphoma
02/23
02/23
NCT03758287: Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Active, not recruiting
1/2
158
RoW
CT053PTSA, Ningetinib, Gefitinib, Iressa
Sunshine Lake Pharma Co., Ltd.
Non-small Cell Lung Cancer
07/23
07/23
NCT05016544: Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer

Recruiting
1/2
48
RoW
inetetamab, Pytotinib
Sun Yat-sen University
Non-small Cell Lung Cancer
08/23
02/25
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting
1/2
183
Japan, US, RoW
Glumetinib, SCC244
Haihe Biopharma Co., Ltd.
C-Met Exon 14 Mutation
10/23
12/23
NCT05102006: Phase Ib/II Clinical Study of LBL-007 in Treatment of Advanced Malignant Tumors

Recruiting
1/2
200
RoW
LBL-007 Injection, LBL-007, Toripalimab Injection
Nanjing Leads Biolabs Co.,Ltd
Advanced Solid Tumor
06/25
08/25
NCT05767866: Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR

Recruiting
1/2
160
RoW
YK-029A
Suzhou Puhe Pharmaceutical Technology Co., LTD
Treatment, Treatment Side Effects
12/23
05/24
NCT05284994: TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer

Recruiting
1/2
160
RoW
TQ-B3525 Tablets, Osimertinib Mesylate Tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Nonsmall-cell Lung Cancer
04/24
06/24
NCT05260385: To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors

Recruiting
1/2
133
RoW
KC1036
Beijing Konruns Pharmaceutical Co., Ltd.
Digestive System Tumors
10/25
12/25
NCT05173805: Phase I Clinical Study of YL-15293 in Patients With Advanced Solid Tumor With KRAS Mutation

Enrolling by invitation
1/2
150
RoW
YL-15293
Shanghai YingLi Pharmaceutical Co. Ltd.
Advanced Solid Tumor
04/24
12/24
PRO1160-001, NCT05721222: PRO1160 for Advanced Solid and Liquid Tumors

Recruiting
1/2
134
US, RoW
PRO1160
ProfoundBio US Co.
Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
11/26
03/27
NCT05824455: A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors

Terminated
1/2
4
RoW
JS109 combine with irinotecan
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd., Sponsor GmbH
Advanced Solid Tumors
09/23
09/23
LBL-007-CN-004, NCT05516914: A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Recruiting
1/2
490
RoW
LBL-007 Injection, LBL-007, Tislelizumab Injection, Tislelizumab, Cisplatin Injection, Cisplatin, Gemcitabine Hydrochloride for Injection, Gemcitabine Hydrochloride, Docetaxel injection, Docetaxel
Nanjing Leads Biolabs Co.,Ltd
Malignant Tumors
10/25
12/25
NCT05505877: Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors

Recruiting
1/2
160
RoW
BR790+Tislelizumab
Shanghai Gopherwood Biotech Co., Ltd.
Advanced Solid Tumor
10/24
12/24
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
 

Download Options